MATCH Arm EAY131-Z1L

**Semantic type:** Intellectual Product

**Definition:** The unique identifier assigned to the arm of the Molecular Analysis for Therapy Choice (MATCH) phase II clinical trial that is investigating treatment with ulixertinib in patients with tumors that have BRAF fusions or BRAF gene mutations, excluding those with BRAF V600E or V600K substitution mutations and central nervous system primary malignancy.

**Synonyms:** - EAY131-Z1L - Z1L